April 7 Quick Takes: ENSEM launches with $67M series A and molecular dynamics platform

Boston-based ENSEM Therapeutics Inc. closed a series A2 financing led by G GV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment and China-based CBC Group, which has incubated the company since 2021; the round brings the company’s total series A financing to $67 million. ENSEM’s Kinetic Ensemble platform integrates molecular simulation, machine learning and experimental validation studies to identify non-obvious binding sites on difficult-to-drug targets. The company plans to develop small molecule therapies for precision cancer indications, and may expand into genetic disorders and other disease areas.

Viz.ai Inc. will grow its customer base and expand its platform to detect and triage additional diseases with its $100 million series D round. The financing, which valued the company at $1.2 billion, was led by Tiger Global and Insight Partners, and saw participation from existing investors including Scale Ventures, Kleiner Perkins, Threshold, GV, Sozo Ventures, CRV and Susa. Viz.ai’s LVO Stroke Platform was cleared by FDA in 2018 to detect large vessel occlusion strokes in computed tomography images of the brain. In 2020, it became the first AI technology to be awarded the New Technology Add-on Payment...